Cargando…

Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS

Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder with complex biology and significant clinical heterogeneity. Many preclinical and early phase ALS clinical trials have yielded promising results that could not be replicated in larger phase 3 confirmatory trials. One re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goyal, Namita A., Berry, James D., Windebank, Anthony, Staff, Nathan P., Maragakis, Nicholas J., van den Berg, Leonard H., Genge, Angela, Miller, Robert, Baloh, Robert H., Kern, Ralph, Gothelf, Yael, Lebovits, Chaim, Cudkowicz, Merit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Invited Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496557/ https://www.ncbi.nlm.nih.gov/pubmed/31899540 http://dx.doi.org/10.1002/mus.26801

Ejemplares similares

A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
por: Cudkowicz, Merit E., et al.
Publicado: (2022)

NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results
por: Berry, James D., et al.
Publicado: (2019)

Serum Ferritin and Metal Levels as Risk Factors for Amyotrophic Lateral Sclerosis
por: Qureshi, Muddasir, et al.
Publicado: (2008)

Developing multidisciplinary clinics for neuromuscular care and research
por: Paganoni, Sabrina, et al.
Publicado: (2017)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort
por: Weisskopf, Marc G., et al.
Publicado: (2015)

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis
por: Cohen, Jeffrey A, et al.
Publicado: (2022)

2219: Amyotrophic lateral sclerosis, stem cells and TALENted technology
por: Kurani, Shaheen, et al.
Publicado: (2018)

Improving clinical trial outcomes in amyotrophic lateral sclerosis
por: Kiernan, Matthew C., et al.
Publicado: (2020)

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model
por: Kaspi, Haggai, et al.
Publicado: (2021)

Key changes in denervated muscles and their impact on regeneration and reinnervation
por: Wu, Peng, et al.
Publicado: (2014)

DNA plasticity and damage in amyotrophic lateral sclerosis
por: Penndorf, Diane, et al.
Publicado: (2018)

Current view and perspectives in amyotrophic lateral sclerosis
por: Mathis, Stéphane, et al.
Publicado: (2017)

Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
por: Genge, Angela, et al.
Publicado: (2023)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Antibody Response to HML‐2 May Be Protective in Amyotrophic Lateral Sclerosis
por: Garcia‐Montojo, Marta, et al.
Publicado: (2022)

Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes
por: Paganoni, Sabrina, et al.
Publicado: (2022)

IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis
por: Wosiski-Kuhn, Marlena, et al.
Publicado: (2019)

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?
por: Giacoppo, Sabrina, et al.
Publicado: (2016)

Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial
por: Smith, Richard, et al.
Publicado: (2017)

Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway?
por: Khalil, Bilal, et al.
Publicado: (2017)

Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis
por: Thonhoff, Jason R., et al.
Publicado: (2022)

Addressing (over)prescribing of opioids in surgery
por: Schäfer, Willemijn L.A., et al.
Publicado: (2020)

The interaction of genetics and environmental toxicants in amyotrophic lateral sclerosis: results from animal models
por: Sher, Roger B.
Publicado: (2017)

The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis
por: Salmon, Kristiana, et al.
Publicado: (2022)

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses
por: Miller, Robert G., et al.
Publicado: (2022)

Profound Muscle Weakness and Pain after One Dose of Actonel
por: Badayan, Irina, et al.
Publicado: (2009)

Is there hope that transpinal direct current stimulation corrects motoneuron excitability and provides neuroprotection in amyotrophic lateral sclerosis?
por: Bączyk, Marcin, et al.
Publicado: (2021)

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [(11)C]-PBR28
por: Zürcher, Nicole R., et al.
Publicado: (2015)

Presidential address: recent advance of mycorrhizal research in China
por: Guo, Liang-Dong
Publicado: (2018)

Olfactory dysfunction in amyotrophic lateral sclerosis
por: Viguera, Cristina, et al.
Publicado: (2018)

Long COVID: what is known and what gaps need to be addressed
por: Krishna, Benjamin, et al.
Publicado: (2023)

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis
por: Berry, James D., et al.
Publicado: (2013)

Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis
por: Salter, Matthew, et al.
Publicado: (2018)

Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis
por: Alshikho, Mohamad J., et al.
Publicado: (2016)

Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension
por: Schutte, Aletta E, et al.
Publicado: (2022)

Prospects for bone marrow cell therapy in amyotrophic lateral sclerosis: how far are we from a clinical treatment?
por: Gubert, Fernanda, et al.
Publicado: (2016)

Apolipoprotein B-100-mediated motor neuron degeneration in sporadic amyotrophic lateral sclerosis
por: Wong, Jamie K, et al.
Publicado: (2022)

A Call to Action to Address the Burden of Cardiovascular Disease in People with Diabetes
por: Lorenty, Karolay, et al.
Publicado: (2022)

Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery
por: Gwinn, Katrina, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_64t8k4gg7c3d6jjbc6js8hjhvk